- Home
- INKT vs ANEB Comparison
INKT vs ANEB Comparison
Compare INKT & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- ANEB
- Stock Information
- Founded
- INKT 2017
- ANEB 2020
- Country
- INKT United States
- ANEB United States
- Employees
- INKT N/A
- ANEB N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- ANEB Health Care
- Exchange
- INKT Nasdaq
- ANEB Nasdaq
- Market Cap
- INKT 69.2M
- ANEB 111.8M
- IPO Year
- INKT 2021
- ANEB 2021
- Fundamental
- Price
- INKT $14.00
- ANEB $2.56
- Analyst Decision
- INKT Buy
- ANEB Buy
- Analyst Count
- INKT 3
- ANEB 2
- Target Price
- INKT $37.50
- ANEB $8.00
- AVG Volume (30 Days)
- INKT 38.6K
- ANEB 29.1K
- Earning Date
- INKT 11-13-2025
- ANEB 11-12-2025
- Dividend Yield
- INKT N/A
- ANEB N/A
- EPS Growth
- INKT N/A
- ANEB N/A
- EPS
- INKT N/A
- ANEB N/A
- Revenue
- INKT N/A
- ANEB N/A
- Revenue This Year
- INKT N/A
- ANEB N/A
- Revenue Next Year
- INKT N/A
- ANEB N/A
- P/E Ratio
- INKT N/A
- ANEB N/A
- Revenue Growth
- INKT N/A
- ANEB N/A
- 52 Week Low
- INKT $4.56
- ANEB $0.80
- 52 Week High
- INKT $76.00
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- INKT 44.85
- ANEB 56.80
- Support Level
- INKT $13.81
- ANEB $2.30
- Resistance Level
- INKT $15.00
- ANEB $2.74
- Average True Range (ATR)
- INKT 0.82
- ANEB 0.14
- MACD
- INKT -0.04
- ANEB 0.03
- Stochastic Oscillator
- INKT 15.16
- ANEB 65.00
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.